Therapeutic induction of Helicobacter pylori bacteraemia in multiple sclerosis: How far from reality?

Medical Hypotheses

Volumn 71, Issue 4, 2008, Pages 610-611

  Prasad, Hari ^a   Krishnaprasad, M S ^a   Karnaker, Vimal Kumar ^a  

^a NITTE DEEMED TO BE UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LIPOPOLYSACCHARIDE; NANOPARTICLE; PROBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTEREMIA; CHRONIC INFLAMMATION; HELICOBACTER PYLORI; LETTER; MULTIPLE SCLEROSIS; PARTICLE SIZE; PRIORITY JOURNAL;

BACTEREMIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MODELS, THEORETICAL; MULTIPLE SCLEROSIS;

HELICOBACTER PYLORI;

EID: 50849091262     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.05.025     Document Type: Letter

References (6)

1. Pezeshki M.Z., Zarrintan S., and Zarrintan M.H. Helicobacter pylori nanoparticles as a potential treatment of conventional multiple sclerosis. Med Hypotheses 70 (2008) 1223
2. Morrow Jr. K.J., Bawa R., and Wei C. Recent advances in basic and clinical nanomedicine. Med Clin North Am 91 (2007) 805-843
3. Blaser M.J. Helicobacter pylori and Other Gastric Helicobacter Species. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Mandell Douglas and Bennett's principles and practice of infectious diseases. 6th ed. (2005), Elsevier Churchill Livingstone, Philadelphia, USA 2557-2563
4. Li W., Minohara M., Su J.J., et al. Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. J Neuroimmunol 184 (2007) 227-231
5. Wender M. Prevalence of Helicobacter pylori infection among patients with multiple sclerosis. Neurol Neurochir Pol 37 (2003) 45-48
6. Pérez-Pérez G.I., Shepherd V.L., Morrow J.D., et al. Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun 63 (1995) 1183-1187